AzTrials
AzTrials

Multiple Sclerosis,Gait, ExerciseNCT05529498

High Intensity Interval Gait Training in Multiple Sclerosis

A study testing Moderate paced continuous gait training and High Intensity Interval gait training in people with Multiple Sclerosis,Gait, Exercise, run by City University of New York at 1 site in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Over 90% of persons with MS (pwMS) complain of difficulty with walking. High intensity interval gait training (HIIGT), where persons alternate brief periods of walking at high speeds with periods of rest has been found to improve walking in other neurologic diagnoses. However its impact on pwMS is not known. Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Multiple Sclerosis,Gait, Exercise
What is being tested?
Moderate paced continuous gait training and High Intensity Interval gait training
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteUnited States
Study dates
2 Sep 2022to 31 Dec 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Inclusion Criteria: Persons diagnosed with Multiple Sclerosis. Rationale:because we are studying effects of the intervention on participant with MS

  • The ability to walk for 6 minutes continuously with or without assistive device. Rationale:we are using the 6MWT as our primary outcome measure
  • The ability to read, understand and sign a consent form so that they are able to understand the study we are doing
  • Above the age of 18 because they have to be able to give consent for the study
  • English speaking as we do not have the resources for translation for the multiple sessions this study entails

Exclusion Criteria:Any cardiopulmonary, orthopedic, or non-MS neurologic disease as we are only examining the effects of MS and need to rule out the impact of other conditions

  • Report of a recent exacerbation. Rationale: the impact of the rationale can interfere with the impact of the independent variables

Trial locations and contacts

1 site in 1 country.

Herbert Karpatkin, DSc contact

212-396-7115

hkarpatk@hunter.cuny.edu

Jaya Rachwani, PhD contact

(212) 481-4321

jr5856@hunter.local

United States1 site, 1 recruiting
  • Hunter College

    New York, New York, 11238

    Herbert Karpatkin, DSc, 212-396-7115, hkarpatk@hunter.cuny.edu

    Recruiting

Other trials in United States

About this study

Official title: Effect of High Intensity Interval Gait Training on Ambulation in MS

Over 90% of persons with MS (pwMS) complain of difficulty with walking. High intensity interval gait training (HIIGT), where persons alternate brief periods of walking at high speeds with periods of rest has been found to improve walking in other neurologic diagnoses. However its impact on pwMS is not known. Most gait training in MS is done continuously at a slower pace. The purpose of this study is to compare the effects of HIIGT to traditional Moderate Intensity Continuous Gait Training (MICGT) in pwMS.

Read the detailed description

Purpose: To determine whether pwMS will have greater improvements in gait with HIIGT as compared to MICGT.

Primary Question: Does HIIGT results in greater improvements in gait parameters in pwMS than MICGT? Secondary question: Will HIIGT result in greater improvements in balance, lower extremity strength, lower extremity range of motion and HR when compared to MICGT in pwMS?

Hypothesis: HIIGT will result in greater improvements in gait parameters in pwMS than MICGT.

Justification: Previous research has shown that MICGT, moderate intensity interval training and high intensity non-gait interval training is effective in pwMS (1)(2). HIIGT has been shown to be effective in persons with stroke (3) but the effects of HIIGT on pwMS are not known.

Outcomes and dissemination of information: We will present our findings at national conferences and submit manuscripts of our findings to the appropriate peer reviewed journal.

The answers to our research questions will be found by using a randomized controlled to group people pretest post test design.

  1. - INFORMED CONSENT: Upon entering Hunter College Physical Therapy department, participants will be greeted by dr. Karpatkin and provided with an informed consent form outlining the purpose of the study, the length of the study, the potential risks, and the procedures.
  2. - COLLECTION OF DEMOGRAPHICS: Participants will fill out a questionnaire collecting demographics and subject characteristics information, such as age, gender, race, phenotype of MS, ambulatory device used, medications used, years since diagnosis.
  3. - COLLECTION OF SELF REPORT MEASURES: Patients will then will out the following self report questionnaires Multiple Sclerosis Impact Scale 29 (MSIS 29): The MSIS 29 is a questionnaire asking for participants' views about the impact of MS on their day-to-day life, measuring coordination, fatigue, flexibility, muscle performance, muscle tone/spasticity, balance/falls, reach and grasp, self-care, health and wellness, leisure, quality of life, role function, social function, work in pwMS.

The Fatigue Severity Scale (FSS): The FSS is a short questionnaire that requires you to rate your level of fatigue. The FSS questionnaire contains nine statements that rate the severity of your fatigue symptoms. Read each statement and circle a number from 1 to 7, based on how accurately it reflects your condition during the past week and the extent to which you agree or disagree that the statement applies to you.

12 Item MS Walking Scale (MSWS-12): is a self-report measure of the impact that MS has on an individual's ambulation. The participants read each statement and report how much MS has limited them in the past two weeks on a scale of 1 to 5.

4 - 6 minute walk test (6MWT): The 6MWT measures the distance an individual is able to walk over a total of six minutes on a leveled surface indoors. The goal is for the individual to walk as far as possible in six minutes. The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway. We will also be measuring the distance walked in each minute of the test and participants heart rate before, during and after the test.

5 - The Functional Gait Assessment (FGA): is used to assess postural stability and balance during different tasks in populations of pwMS, Parkinson disease, spinal cord injuries, stroke diagnosis, and vestibular disorders. FGA is a modification of the Dynamic Gait Index and was created to help decrease the ceiling effect and improve reliability.

6 - Hand Held Dynamometry (HHD): is used to measure participants' strength in hip flexion, hip extension, knee flexion, knee extension, ankle plantarflexion and dorsiflexion. Measurements will be taken using a dynamometer.

7 - Goniometry: is used to measure ranges of motion for participants' hip flexion, hip extension, knee flexion, knee extension, ankle plantarflexion, and ankle dorsiflexion. Measurements will be taken using a standard goniometer.

8 - RANDOMIZATION INTO HIIGT GROUP AND MICGT GROUP: After collecting the information from the questionnaires, the participants who meet the inclusion criteria will be randomly assigned each participant into either the HIIGT or MICGT group, with each group having an equal number of participants per group. Randomization will be achieved by the participant pulling odd or even numbers out of a hat. An even number will be placed in the HIIGT group and an odd number into the MICGT group. Since the HIIGT represents a novel therapy it will be considered the experimental group. Since the MICGT represents the standard of care it will be considered the control group 7 - DESCRIPTION OF HIIGT PROTOCOL: The protocol for HIIGT will be a total of 4 to 5 weeks including 4 weeks of the intervention, one day of pre-testing and one day of post-testing. Training entails a total of 25 minutes work with 3 minutes warm up of gentle walking, then multiple rounds of 30 seconds of fast walking followed by 60 seconds of seated rest. Fast walking will be defined to the participant as walking the fastest they can comfortably. The participants will complete the cycle of 30 seconds work with 60 seconds rest until they get to 23 minutes of total exercise and then a 2 minute cool down to make 25 minutes of total work. During the intervention each participant's heart rate, Rate of Perceived Exertion, and distance walked will be recorded with a measuring wheel. During the entire protocol, Dr. Karpatkin will be guarding the participant and a wheelchair will be following the participant.

8- DESCRIPTION OF MICGT PROTOCOL: The protocol for MICGT will be a total of 4 to 5 weeks including 4 weeks for the intervention, one day for pre-testing, and one for post-testing. They will engage in continuous moderate walking for 25 minutes per session, 3 times a week for 4 weeks. Moderate walking is defined as a pace the participant is able to comfortably maintain for the 25 minutes. Dr. Karpatkin will be guarding during the full training, and a wheel chair will follow behind the participant. During the intervention each participant's heart rate, Rate of Perceived Exertion, and distance walked will be recorded with a measuring wheel.

9 - POST-TEST PROTOCOL: The post-test protocol will be the same as the pre-test. Each participant will complete the 6MWT, HHD for the lower extremity, Goniometric measures for the lower extremity, and the FGA.

Gate endurance will be operationally defined by performance on the six minute walk test.

Fatigue will also be operationally defined by performance on the six minute walk test.

Balance performance will be operationally defined by performance on the functional gait assessment tool. Lower extremity strength will be operationally defined as performance on handheld dynamometry.

Lower extremity range of motion improvements will be operationally defined as pretest post test improvements in goniometry.

Improvements in heart rate will be measured using pulse oximetry.

Data analysis plan:For all primary outcomes with ratio level data, we will conduct a 2X2 mixed-factor Analysis of Variance (ANOVA). The between-factor will be group type (HIIGT vs MIGGT) and the within-factor will be time (pre-test vs post-test). For the FGA scores (ordinal level data), we will use Generalized Estimating Equations GEEs instead.

We expect a homogenous sample in terms of age, gender, disease severity, and years since onset. However, prior to conducting statistical analyses, we will test the relationship between subject age, disease severity, and years since onset with primary outcome measures using Pearsons correlations (for ratio data) and Spearman's rank correlation (for ordinal data). We will use unpaired t-tests to compare differences in outcome measures between males and females. If any of the subject-characteristic measures have a significant effect on the primary outcome measures, they will be included as covariates or factors in the ANOVA model or GEEs

Being tested
Moderate paced continuous gait training, High Intensity Interval gait training
Medical subject headings
Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Moderate paced continuous gait trainingBehavioural

    walking continuously for 20 minutes at a moderate pace

  • High Intensity Interval gait trainingBehavioural

    20 minutes of interspersing 30 seconds of fast walking with 1 minute of rest

Study groups in NCT05529498
Study groupRoleWhat they receive
ExperimentalExperimentalHigh intensity interval gait training
Receives: Behavioral: High Intensity Interval gait training
ControlActive comparatorModerate intesnity continuous gait training
Receives: Behavioral: Moderate paced continuous gait training

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 6 minute walk test

    Distance covered during continuous walking for 6 minutes

    Measured: 6 minutes

Secondary outcomes (1)
  1. Finctional gait assessment

    balance during walking

    Measured: 10 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Sep 2022
  2. Study start2 Sep 2022
  3. Primary completion31 Dec 2023 (estimated)
  4. Study completion31 Dec 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
2 group pretest postest
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05529498
Sponsor's protocol ID
CityUNewYork
Status last verified
Sep 2022
First submitted
2 Sep 2022
Last updated
7 Sep 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Moderate paced continuous gait training and High Intensity Interval gait training in people with Multiple Sclerosis,Gait, Exercise, run by City University of New York at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 7 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Herbert Karpatkin, DSc (212-396-7115, hkarpatk@hunter.cuny.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

6 minute walk test (time frame: 6 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Sep 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in